



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61L 25/00, 15/28, 15/60</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/16746</b> <b>(43) International Publication Date:</b> 4 August 1994 (04.08.94)
<b>(21) International Application Number:</b> PCT/GB94/00114 <b>(22) International Filing Date:</b> 20 January 1994 (20.01.94) <b>(30) Priority Data:</b> 9301258.1 22 January 1993 (22.01.93) GB <b>(71) Applicant (for all designated States except US):</b> COUR- TAULDS PLC [GB/GB]; 50 George Street, London W1A 2BB (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> BAHIA, Hardev, Singh [GB/GB]; 18 St. Lukes Road, Coventry CV6 4JA (GB). BURROW, Thomas, Richard [GB/GB]; 207 Albany Road, Coventry CV5 6NF (GB). <b>(74) Agent:</b> HALE, Stephen, Geoffrey; J.Y. & G.W. Johnson, Furnival House, 14-18 High Holborn, London WC1V 6DE (GB).		<b>(81) Designated States:</b> AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> WOUND DRESSINGS  <b>(57) Abstract</b>  A wound dressing is characterised in that the wound-contacting surface thereof comprises carboxymethyl cellulose filaments capable of absorbing at least 15 times their own weight of 0.9 % by weight aqueous saline solution (as measured by the free-swell absorbency test) to form a swollen transparent gel. The dressing when thus swollen to form a transparent gel retains sufficient fibrous character to be removed as a coherent dressing from a wound. The carboxymethyl cellulose filaments can be used to treat a traumatic surgical or chronic wound.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

WOUND DRESSINGSTechnical Field

This invention relates to wound dressings, which term also includes bandages and swabs for application to wounds including wounds consequent upon surgical operations, and to the use of absorbent fibre in dressings. The invention is especially applicable to dressings for deep-seated or chronic wounds such as ulcers.

Background Art

10       The use of absorbent materials, particularly absorbent polysaccharide materials, at the wound-contacting surface of wound dressings is known. Dressings comprising alginate fibres are described, for example, in GB-A-1394742, GB-A-2103993, US-A-4421583, EP-A-227955, EP-A-236104, EP-A-15 243069 and WO-89/12471. GB-A-1329693 describes a dressing comprising a substrate bearing a haemostatic material comprising an alginate and a water-soluble polymer such as sodium carboxymethyl cellulose.

US-A-3731686 describes an absorbent dressing including a 20 compressed body comprised of absorbent fibres of an alkali metal salt of carboxyalkyl cellulose having an average degree of substitution greater than 0.35 carboxyalkyl radicals per anhydroglucose residue, said absorbent fibres of an alkali metal salt of carboxyalkyl cellulose being 25 heat-treated so as to become insoluble but swellable in water at room temperature. The dressing is typically a tampon, sanitary napkin or diaper having a core of the compressed absorbent fibres. US-A-3589364 relates to bibulous water-insoluble cellulosic fibres which retain the 30 fibrous form of the original cellulose raw material and are prepared by wet-crosslinking fibres of a water-soluble carboxymethyl cellulose salt. The fibres are suggested for use in a tampon, surgical dressing, surgical sponge, catamenial napkin or diaper. US-A-4634438 and US-A-4634439

- 2 -

describe a hygienic pH-regulating product for topical application, particularly a catamenial device, comprising a homogeneous mass of carboxyalkyl-modified cellulose fibres of degree of substitution 0.01 to 0.30 wherein the 5 carboxyalkyl groups are in the free acid form.

Wound dressings containing a water-absorbent polymer such as sodium carboxymethyl cellulose are described in GB-A-1548678 and EP-A-92999 and in the books "Wound Management and Dressings" by S. Thomas (The Pharmaceutical Press) at 10 pages 55-61 and "Advances in Wound Management" edited by T.D. Turner et. al (J. Wiley) at pages 89-95, and in the article by S. Thomas in J. Wound Care, Vol.1 (1992) No. 2, pages 27-30. These dressings, generally known as hydrocolloid dressings, contain the water-absorbent polymer 15 in powder form in an elastomeric and/or adhesive matrix such as polyisobutylene; the resulting material forms the wound-contacting layer of the hydrocolloid dressing. The hydrocolloid dressing takes up wound fluid to form a gel that produces a moist environment which facilitates healing. 20 The absorbent component of the dressing is also produced in the form of granules or paste for the treatment of small cavities.

#### Disclosure of Invention

According to the present invention, a wound dressing 25 is characterised in that the wound-contacting surface thereof comprises carboxymethyl cellulose filaments capable of absorbing at least 15 times their own weight of 0.9% by weight aqueous saline solution (as measured by the free-swell absorbency test) to form a swollen transparent gel and 30 that the dressing when thus swollen to form a transparent gel retains sufficient fibrous character to be removed as a coherent dressing from a wound. The filaments may be in the form of continuous filaments or cut fibre, for example staple fibre, or of strands or fabrics made therefrom. The 35 strands can be any linear textile material formed from the filaments or fibre, for example a yarn, sliver, roving or

- 3 -

rope. The carboxymethyl cellulose filaments can for example be used as a tow or as a fabric.

In the free-swell absorbency test, 0.5g of the carboxymethyl cellulose filaments, which have been 5 conditioned at 65% relative humidity and 20°C before being tested, is dispersed in 30cc 0.9% by weight aqueous saline solution and left for 5 minutes. The dispersion is then filtered through a sintered Mark 1 funnel of pore size 100-160 microns and is left for 5 minutes, or until it stops 10 dripping, whichever is the longer. The water filtered through the funnel is weighed and the weight of water absorbed by the filaments is calculated by subtraction.

The tow, strand or fabric of carboxymethyl cellulose filaments forming the wound-contacting surface of the 15 dressing is preferably capable of absorbing at least 25 times its own weight of 0.9% by weight aqueous saline solution as measured by the free-swell absorbency test. The carboxymethyl cellulose filaments are preferably at least 15 mm long, most preferably at least 30 mm long, although 20 cut fibre of shorter staple length down to 6 mm or even 3 mm can be used in certain nonwoven fabric constructions.

Dressings according to the invention using carboxymethyl cellulose filaments at the wound-contacting surface have many of the advantages in wound-healing 25 properties of known hydrocolloid dressings based on carboxymethyl cellulose powder and have additional advantages of being easier to handle and apply to a wound. The filaments do not need to be mixed with any other material such as the adhesive used in known hydrocolloid 30 dressings. The dressings of the invention are also easier to remove from a wound without causing mess, or damage to the wound. A dressing in which the carboxymethyl cellulose filaments are used as the only layer covering the wound has the additional advantage that the dressing can form a 35 transparent gel in use, allowing observation of the wound without disturbing the dressing.

The dressings of the invention are distinguished from materials described in US-A-3731686 and US-A-3589364 in that the carboxymethyl cellulose filaments used in the present invention need not be crosslinked in order to be effective.

5 The fibres described in US-A-3731686 and US-A-3589364 are generally derived from natural cellulose sources, and they are most commonly short fibres such as wood pulp fibres. When carboxymethylated, such short fibres require crosslinking to prevent complete dissolution and to maintain

10 a coherent structure. The crosslinked fibres are water-swellaable but are not water-soluble. The non-crosslinked carboxymethyl cellulose filaments used in the present invention will partially dissolve in aqueous liquids just as the carboxymethyl cellulose powder in known hydrocolloid

15 dressings does. When long filaments (at least 15 mm) are used according to the present invention they prevent complete dissolution of the dressing and give a gel which is sufficiently coherent to be removable in one piece. A dressing according to the invention containing somewhat

20 shorter filaments which are not crosslinked but are held securely in a nonwoven fabric construction can also form a gel which is removable as a coherent dressing. Crosslinking may, however, be used to alter the properties of the filaments used in the present invention, for example to

25 reduce or eliminate dissolution of the fibres.

The carboxymethyl cellulose filaments are generally prepared by reacting cellulose filaments with a strong alkali and with monochloroacetic acid or a salt thereof.

The preferred cellulose filaments are solvent-spun

30 cellulose filaments spun from a solution of cellulose in a solvent, as opposed to regenerated cellulose fibres which are spun from a solution of a cellulose derivative (cellulose xanthate) which is re-converted to cellulose in a spin bath into which the fibres are spun. Examples of

35 solvents for cellulose are tertiary amine N-oxides, N,N-dimethyl formamide/nitrogen tetroxide mixtures, dimethyl sulphoxide/paraformaldehyde mixtures and solutions of

- 5 -

lithium chloride in N,N-dimethyl acetamide or N-methyl pyrrolidone. The preferred solvents for use in producing solvent-spun cellulose filaments are tertiary amine N-oxides. The production of solvent-spun cellulose filaments is described for example in US-A-4246221 and US-A-4196281 which give examples of preferred tertiary amine N-oxides. The solution of cellulose is spun through an air gap into a bath of a non-solvent for cellulose, usually water, where the cellulose is precipitated in fibre form.

10       The carboxymethyl cellulose filaments can alternatively be produced from regenerated cellulose filaments, cuprammonium rayon or cotton fibres but carboxymethyl cellulose filaments produced from solvent-spun cellulose have higher absorbency and superior physical  
15 properties. The absorbency of 0.9% by weight saline solution, as measured by the free-swell method, of carboxymethyl cellulose filaments derived from solvent-spun cellulose can for example be 20-40 grams per gram, combined with a tenacity in the range 25-15cN/tex. Viscose rayon or  
20 cotton fibres carboxymethylated by the same process have absorbencies only in the range 8-13 g/g and a lower tenacity. Carboxymethyl cellulose filaments formed from polynosic viscose rayon have increased absorbency and tenacity compared to carboxymethyl cellulose filaments  
25 formed from other types of viscose rayon, but they have less absorbency and tenacity compared to carboxymethyl cellulose filaments formed from solvent-spun cellulose. Solvent-spun cellulose filaments have a substantially uniform structure across their cross-section and have greater crystallinity  
30 than regenerated cellulose or cotton fibres, which both have a structure which includes a relatively dense skin at the surface of the fibre.

When carrying out carboxymethylation the alkali and the monochloroacetic reagent can be applied to the cellulose  
35 filaments simultaneously or sequentially. The cellulose filaments are preferably in the form of a tow, but they can alternatively be in the form of yarn, staple fibre or

- 6 -

fabric, for example a woven, knitted or nonwoven fabric.

Any finish present on the tow, yarn, fibres or fabric should preferably be removed by scouring before the carboxymethylation reaction, particularly if it is a hydrophobic finish. The yarn, tow or fibre can be a blend of the cellulose filaments with another fibre such as polyester or nylon, which is unaffected by the carboxymethylation process. A tow can be of dry filaments as commercially sold or it can be a tow of never-dried filaments, that is filaments which have not been dried after filament formation. The rate of uptake of reagents by the filaments may be somewhat faster using never-dried filaments.

The alkali and the monochloroacetic reagent are preferably applied from aqueous solution or from solution in a mixture of water and a polar organic solvent. The alkali is preferably an alkali metal hydroxide such as sodium hydroxide or potassium hydroxide and is preferably used at a concentration of at least 2% by weight, most preferably 5% or more, up to 15% by weight, most preferably up to 10%. The monochloroacetic reagent is preferably used in salt form, usually the salt corresponding to the alkali used, for example sodium monochloroacetate with sodium hydroxide. The monochloroacetate is preferably used at a concentration of at least 5% by weight, most preferably at least 10%, up to 35% by weight, most preferably up to 25%.

The alkali, for example sodium hydroxide, and monochloroacetic reagent, for example sodium monochloroacetate, are preferably applied to the cellulose filaments simultaneously. A solution containing the required concentration of sodium hydroxide and sodium monochloroacetate can be prepared by mixing solutions of these reagents which have been separately prepared or by dissolving sodium hydroxide in a solution of sodium monochloroacetate. When preparing a reagent solution in aqueous organic solvent, sodium hydroxide can for example be



- 7 -

dissolved in water at up to 35% by weight and sodium monochloroacetate at up to 45% by weight and the solutions can be diluted with an alcohol such as ethanol or industrial methylated spirits to give the required concentration of reagents in the aqueous organic solvent mixture. The mixed solution can be applied by immersion of the filaments in the reagent solution in a reaction vessel at elevated temperature, for example at least 50°C up to the boiling point of the solution, for a time sufficient to carry out the carboxymethylation reaction, for example from 10 minutes to 8 hours, preferably 0.5 to 4 hours. Reaction in solution in this manner generally gives good uniformity of degree of substitution as between filaments, and compressed air may be bubbled through the reagent solution to enhance this uniformity. This type of reaction is generally carried out as a batch process.

Alternatively, the reagent solution can be applied by padding, for example to a liquid takeup of 50-300% by weight, optionally followed by mangling, and drying at elevated temperature, for example 50-200°C, preferably at least 80°C and up to 150°C. The filaments are preferably dried to a moisture content of 5 to 20% by weight to avoid brittleness. The solution containing both sodium hydroxide and sodium monochloroacetate should preferably not be held for an extended time at an elevated temperature. The sodium hydroxide and sodium monochloroacetate solutions can be mixed just before application to the filaments, or the separate solutions can simultaneously be sprayed onto the filaments, for example by sprays arranged at right angles to each other. If the mixed solution of sodium hydroxide and sodium monochloroacetate has to be stored, it is preferably held at a temperature of 20°C or below, for example 0 to 5°C. Storage at 20-40°C of filaments treated with both the alkali and the monochloroacetate is preferably avoided. It is usually most convenient to heat the filaments immediately after padding to effect the carboxymethylation reaction. Alternatively, the padded filaments can be stored at a temperature below 20°C, preferably in the range 0 to 5°C,

- 8 -

before heating. It may be preferred to carry out padding at a temperature below 20°C, for example 0 to 10°C.

The degree of substitution of the cellulose filaments achieved is preferably at least 0.15 carboxymethyl group per glucose unit, and is most preferably at least 0.2 and less than 0.5. A degree of substitution in the range 0.25 to 0.45 may be particularly suitable. Higher degrees of substitution than 0.5 carboxymethyl group per glucose unit can be used, for example up to 1.0, but they may lead to filaments which are too readily water-soluble rather than water-swellable.

It is believed that the degree of carboxymethylation is not uniform across the cross-section of the filaments; the filaments generally have a higher degree of substitution in the surface region than at the core of the filament. This may be advantageous since the less substituted core contributes greatly to the strength of the filaments in the swollen state. This strength allows the dressing to be pulled from the wound as a coherent dressing. This is an advantage of cellulose filaments which have been carboxymethylated, as against a swellable polymer which has been formed into filaments.

After the carboxymethylation process, the filaments are usually washed to remove any unreacted alkali or chloroacetate or any by-products such as sodium chloride or sodium glycollate. An aqueous wash is generally used, preferably a mixture of water with a water-miscible organic solvent. The washing medium may contain a surfactant and/or an acid. A low molecular weight mono-alcohol such as ethanol or methanol is preferably used as water-miscible organic solvent, for example a preferred washing medium is based on a mixture of water and ethanol in weight ratio 2:1 to 1:2. If a surfactant is used it is preferably a non-ionic surfactant such as a polyalkylene oxide adduct of an alcohol or phenol, although anionic or cationic surfactants can be used. Any surfactant used should preferably be

hydrophilic rather than hydrophobic. Examples of preferred surfactants are those sold under the Trade Marks "Tween 20" and "Atlas G1086". Any acid used during washing to neutralise the alkalinity of the carboxymethylated filaments 5 is preferably a weak acid, for example an organic carboxylic acid such as acetic acid or citric acid. The carboxymethylated filaments are preferably neutral for use in most wound dressings; the filament pH is preferably in the range 5.5 to 8. At this pH the carboxymethyl groups are 10 mainly in the anion form rather than free acid form. Dressings of acidic or alkaline pH, as well as neutral dressings, have been suggested for particular wounds, and the amount of acid used in the washing medium can be adjusted to give the desired pH for the filaments.

15 As an alternative to inclusion of a surfactant in the wash liquid, it may be preferred to apply a surfactant subsequently as a finish. It can for example be applied as a solution in alcohol or in an aqueous alcohol mixture, for example the mixture used to wash the filaments, or a liquid 20 surfactant can be applied undiluted. The finish can be applied by immersion of the filaments in the finish, or it can be applied by lick roller or by spray. If the surfactant is applied as a finish, the filaments are preferably pressed to remove any excess wash liquor, for 25 example by mangling, before applying the finish.

After the required washes, the filaments are generally dried, preferably to a moisture content of 5-20% by weight.

The form of the carboxymethylated filaments after swelling in an aqueous liquid such as saline solution depends on the 30 absorbency of the filaments and the diameter of the filaments. Absorbency generally increases with increasing carboxymethyl group content. At high levels of absorbency, particularly if the filaments are of a low decitex, the swollen filaments tend to form a coherent gel in which the 35 identity of individual filaments cannot be discerned, although the gel retains sufficient fibrous character to be

- 10 -

removed as a coherent dressing. For example, filaments of initial decitex 1.7 per filament and having an absorbency (free-swell) of 28, corresponding to treatment with 19.2% by weight  $\text{ClCH}_2\text{COONa}$  and 6.5%  $\text{NaOH}$ , swell to such a gel.

5 Filaments of the same initial decitex, treated with 13.3%  $\text{ClCH}_2\text{COONa}$  and 4.5%  $\text{NaOH}$  and having an absorbency of 20, remain as discrete swollen gel filaments. Filaments of initial decitex 6.0, treated with 22.1%  $\text{ClCH}_2\text{COONa}$  and 7.5%  $\text{NaOH}$  and having an absorbency of 27, also remain as discrete

10 swollen gel filaments. Dressings according to the invention using carboxymethyl cellulose filaments are effective whether they swell to a coherent gel or to discrete gel filaments.

The carboxymethyl cellulose filaments can be used in

15 the dressings in the form of a tow, strand or fabric, for example a yarn of continuous filaments or a yarn formed from staple fibres, or a strand which is a sliver or roving or rope of corded staple fibre, provided that the strand is sufficiently coherent when dry and when swollen to be

20 applied to and removed from a wound, or as a woven, knitted or nonwoven fabric. For example, a cut length of carboxymethyl cellulose filament tow, usually of length at least 3 cm and preferably greater than 10 cm, for example in the range 15 to 30 cm, can be applied directly to the

25 surface of a wound and spread out to cover the whole of the wound. If the wound-contacting surface is formed from a tow of carboxymethyl cellulose filaments, the filaments preferably extend right across the dressing. A rope of carboxymethyl cellulose filaments formed by carding

30 carboxymethyl cellulose staple fibre of length at least 15 mm may be used in a similar way. A dressing of this type would be covered in use with a secondary dressing which is preferably transparent, such as a transparent, water-vapour-permeable film, for example an adhesive-coated polyurethane

35 film such as that sold under the Trade Mark "OpSite".

The carboxymethyl cellulose filaments may be processed into the form of a woven, knitted or nonwoven fabric to

- 11 -

produce a flat dressing which may be applied directly to the surface of a wound. A nonwoven fabric can for example be formed by randomly laying, for example dry-laying, or crosslaying the filaments followed by needling. An  
5 alternative nonwoven fabric can be formed by crosslaying the carboxymethyl cellulose filaments while partially wet with water, followed by drying, optionally under pressure.

The tow, strand or fabric which forms the wound-contacting surface layer of the dressing of the invention  
10 most preferably consists essentially of the carboxymethyl cellulose filaments without any other type of filaments and without any other added material such as adhesive. In such a layer consisting essentially of 100% carboxymethyl cellulose filaments the filaments are generally at least 15  
15 mm long. Alternatively, a woven, knitted or nonwoven fabric dressing may contain up to 80%, preferably up to 50%, by weight, based on total weight, of physiologically inert fibres such as non-carboxymethyl cellulose fibres, polyester fibres, nylon fibres or polyolefin fibres. In such a  
20 fabric, the carboxymethyl cellulose filaments are preferably at least 15 mm long, but shorter filaments, for example 10 mm staple fibre, can be used, particularly in a nonwoven fabric. A nonwoven fabric can, for example, be formed by dry-air-laying a mixture of carboxymethyl cellulose fibres  
25 and thermoplastic fibres on a permeable conveyor above suction apparatus and consolidating the layer so formed by heating to fuse the thermoplastic fibres at their point of contact. The thermoplastic fibres are preferably polyolefin fibres, for example polyethylene or polypropylene fibres or  
30 the bicomponent polyolefin fibres sold under the Trade Mark "Celbond". The dry-laid fabric can alternatively be bonded by consolidating with a latex adhesive.

A fabric of carboxymethyl cellulose filaments for use as a dressing can alternatively be produced by treating a  
35 fabric of cellulose filaments with a strong alkali and with monochloroacetic acid or a salt thereof. The fabric treated can for example be a woven, knitted, needled or

- 12 -

hydroentangled fabric and can consist wholly of cellulose filaments or may include another fibre, such as polyester, nylon or polyolefin, which is physiologically inert and unaffected by the carboxymethylating reagents. Such other  
5 fibre can for example be present at up to 80%, preferably up to 50%, by weight of the fabric.

The carboxymethyl cellulose filaments may be used as one component of a composite dressing in which the carboxymethyl cellulose filament component, for example tow,  
10 staple fibre or a rope or fabric, is secured to a backing material such as fabric or a flexible plastics material. The carboxymethyl cellulose filament wound-contacting material, for example in tow or fabric form, can extend across a backing in the form of a frame, for example a  
15 polymer foam frame of the type described in EP-A-236104. This may be advantageous for observation of the wound without removal of the dressing if the layer of carboxymethyl cellulose filaments is uncovered or has a transparent film backing extending across the frame.

20 The wound dressing of the invention can be packaged and sterilised by known techniques, for example by gamma-irradiation. The wound-contacting layer of the dressing can be moistened by sterilised water before application to the wound if desired.

25 Upon application to the moist surface of a wound the carboxymethyl cellulose filaments absorb the fluid which is exuding from the wound and form a transparent gel. This gel maintains the surface of the wound in a condition which will encourage the natural healing process of the body, that is  
30 the surface of the wound is kept in a moist condition without the presence of excess liquid. When the dressing is saturated, or when there is some other reason for its removal, it can be removed from the surface of the wound in one piece due to its inherent strength. Such removal will  
35 not damage the newly forming tissue at the surface of the wound because the gel at the surface of the filaments

- 13 -

releases readily from the tissue.

### Industrial Applicability

Dressings according to the invention are suitable for the treatment of traumatic, surgical and chronic wounds. 5 The preferred application is for wounds which are exuding moderate to high levels of exudate from their surface. Examples of such wounds are venous ulcers, decubitus ulcers, diabetic ulcers, donor graft sites and infected post-operative wounds.

10 The carboxymethyl cellulose filaments have a further advantage in giving slow release of additives which may be required in a dressing, for example an antiseptic agent or a deodorant, particularly if the additive is applied to the filaments while they are in a swollen state. The additive 15 can for example be included in the last wash liquor applied to the carboxymethyl cellulose filaments, or it can be included in a finish bath if a finish is subsequently applied to the filaments before drying.

### Examples

20 The invention is illustrated by the following Examples, in which percentages and ratios are by weight.

#### Example 1

A 33% aqueous solution of sodium hydroxide, a 42% aqueous solution of sodium monochloroacetate and a 95/5 25 mixture of alcohol (industrial methylated spirits, IMS) and water were mixed to produce an aqueous alcoholic solution containing 6.0% sodium hydroxide and 17.8% sodium monochloroacetate. The solution was added without delay to a reaction vessel containing a dried tow of 1.7 decitex 30 solvent-spun cellulose filaments (spun from tertiary amine oxide solution) and heated to 50°C. The tow was allowed to react at this temperature for 180 minutes.

- 14 -

The tow of carboxymethyl cellulose filaments produced was washed in a solution containing 56% IMS, 43% water, 0.7% acetic acid and 0.3% citric acid. The tow was dried to a moisture content of 15%. The filaments had a free-swell 5 absorbency in 0.9% saline solution of 40 g/g.

The tow was cut to 50 mm lengths and a wound dressing was formed by first carding the cut fibre to form an approximately 18 g.m<sup>-2</sup> web, then cross folding this web and needling to give a resultant nonwoven fabric of 10 approximately 100 g.m<sup>-2</sup>, and then a 10 cm x 10 cm square was cut from the fabric. The square of fabric was packaged in a conventional heat-sealed pouch and sterilised using a gamma radiation dose of 25 kGy.

Alternatively, the tow itself, cut for example to 25 15 cm lengths, can be used, after packaging and sterilisation, as the wound-contacting surface of a dressing.

### Example 2

A tow of solvent-spun filaments having a dry filament decitex of 1.7 was obtained in a never-dried state. The tow 20 was passed through a hand mangle. The amount of water left on the tow after mangling was 62%. This wet tow was put in a solution containing 7.5% sodium hydroxide and 22.1% sodium monochloroacetate at room temperature (20°C) for 2 minutes. The padded tow was mangled again. The total pick-up after 25 mangling was 75%. The padded and mangled tow was then reacted in a conditioning cabinet set at 23% RH (relative humidity) and 90°C for five minutes. The amount of water retained on the tow after the treatment was 13%.

After heat treatment the tow was washed in a solution 30 containing 55% industrial alcohol, 42% water, 2.5% acetic acid and 0.5% citric acid. Washed tow was then treated with a finish containing 99% industrial alcohol and 1% Atlas G1086 emulsifier. After this, the tow was dried at a low temperature, leaving some residual moisture on the



- 15 -

filaments. The filaments had a tenacity of 17.5 cN/tex and an extensibility of 12%. The degree of substitution was 0.405 carboxymethyl group per glucose unit. The moisture regain of fully dried filaments at 65% RH was 17%. The free-swell absorbency of the filaments in 0.9% saline solution was 38 g/g.

A dressing was formed from the resulting tow as described in Example 1.

### Example 3

10 Following the procedure of Example 2, a tow of never-dried 1.7 decitex solvent-spun filaments was reacted with a solution containing 6.5% sodium hydroxide and 19.2% sodium monochloroacetate. The carboxymethyl cellulose filaments produced had a free-swell absorbency in 0.9% aqueous saline  
15 solution of 28 g/g and a degree of substitution of 0.375.

A dressing was formed from the resulting tow as described in Example 1.

Another dressing was formed by cutting the tow to 50 mm staple fibre and carding the resultant fibre to form a  
20 sliver or rope. 25 cm lengths of the sliver were packaged and sterilised as described in Example 1.

### Example 4

The process of Example 2 was repeated using a tow of never-dried solvent-spun filaments of dry decitex 3.0. The  
25 carboxymethyl cellulose filaments produced had a free-swell absorbency in 0.9% aqueous saline solution of 31 g/g.

Dressings in fabric or cut tow form were produced from the treated tow, as described in Example 1.

- 16 -

Example 5

A solution of 6.5% sodium hydroxide and 19.2% sodium monochloroacetate was prepared and cooled to -2°C in a treatment bath. A tow of never-dried 1.7 decitex solvent-spun filaments was passed at 5m/min successively through a roller nip of 100 KPa (to reduce the water content to 62% based on dry tow), the above treatment bath, a roller nip of 34 KPa (to give a total solution pick-up of 75%) and a drying cabinet at 90°C/10% RH for 7 minutes. The treated tow was washed as described in Example 2 and was re-dried. The carboxymethyl cellulose filaments produced had a free-swell absorbency in 0.9% saline solution of 34.1 g/g.

A dressing was formed from the tow as described in Example 1.

15

Example 6

A hydroentangled fabric of dry weight 50 g.m<sup>-2</sup> formed from 1.7 decitex solvent-spun cellulosic filaments was collected in the wet state. The fabric was immersed in a reagent solution as described in Example 1, heated to 50°C and allowed to react at this temperature for 180 minutes. The fabric of carboxymethyl cellulose filaments produced was washed in a solution containing 55% IMS, 42% water and 3% acetic acid and dried to a moisture content of 15%. A dressing was formed by cutting a 10 cm x 10 cm square from the fabric for packaging and sterilisation as described in Example 1.

Example 7

A dry hydroentangled fabric of solvent-spun cellulose filaments was wetted with water and then immersed in the reagent solution described in Example 1 and further processed to form a dressing as described in Example 6.

- 17 -

Example 8

A square of 5 cm x 5 cm was cut from the fabric formed in Example 1 and placed centrally on a 10 cm x 10 cm square of "OpSite" adhesive-coated, water-vapour-permeable, polyurethane film. The whole of the exposed surface of the adhesive and the surface of the fabric square was covered with a silicone-coated paper release material. The dressing was packaged and sterilised as in Example 1.

Example 9

10 The tow of carboxymethyl cellulose filaments produced in Example 1 was cut to 50 mm lengths and 50% of the cut fibre was blended with 50% 1.7 dtex 38 mm "Fibro" (Trade Mark) viscose rayon fibre. The blended fibres were carded, formed into a nonwoven fabric and packaged and sterilised as  
15 described in Example 1.

Example 10

The tow of carboxymethyl cellulose filaments produced in Example 1 was cut to 10 mm staple fibre. A blend of 80% of this staple fibre and 20% "Celbond" bicomponent  
20 polyolefin fibre was dry-laid at 40 g.m<sup>-2</sup> by depositing an air suspension of the fibres on a permeable conveyor passing over a suction apparatus. The layer was converted into a nonwoven fabric by passing air at 130°C through the fabric while it was supported on the permeable conveyor, thereby  
25 fusing the "Celbond" fibres to bond the nonwoven fabric.

The nonwoven fabric was cut into squares, packaged and sterilised as described in Example 1.

CLAIMS

1. A wound dressing characterised in that the wound-contacting surface of the dressing comprises carboxymethyl cellulose filaments capable of absorbing at least 15 times their own weight of 0.9% by weight aqueous saline solution (as measured by the free-swell absorbency test) to form a swollen transparent gel and that the dressing when thus swollen to form a transparent gel retains sufficient fibrous character to be removed as a coherent dressing from a wound.
- 10 2. A wound dressing according to claim 1, characterised in that the carboxymethyl cellulose filaments are at least 15 mm long.
3. A wound dressing according to claim 2, characterised in that the carboxymethyl cellulose filaments  
15 are at least 30 mm long.
4. A wound dressing according to any of claims 1 to 3, characterised in that the carboxymethyl cellulose filaments have a degree of substitution of 0.25 to 0.45 carboxymethyl group per glucose unit.
- 20 5. A wound dressing according to any of claims 1 to 4, characterised in that the carboxymethyl cellulose filaments have been prepared by reacting cellulose filaments with a strong alkali and with monochloroacetic acid or a salt thereof.
- 25 6. A wound dressing according to claim 5, characterised in that the cellulose filaments are solvent-spun cellulose filaments.
7. A wound dressing according to claim 5, characterised in that the cellulose filaments are polynosic  
30 viscose rayon filaments.
8. A wound dressing according to any of claims 1 to

- 19 -

7, characterised in that the carboxymethyl cellulose filaments are in the form of a tow, strand or fabric which is capable of absorbing at least 25 times its own weight of 0.9% by weight aqueous saline solution, as measured by the 5 free-swell absorbency test.

9. A wound dressing according to any of claims 1 to 8, characterised in that the wound-contacting surface of the dressing consists essentially of the said carboxymethyl cellulose filaments without any added adhesive material.

10 10. A wound dressing according to claim 9, characterised in that the wound-contacting surface of the dressing is a tow of carboxymethyl cellulose filaments which extend right across the dressing.

11. A wound dressing according to any of claims 1 to 15 8, characterised in that the wound-contacting surface of the dressing comprises at least 50% by weight carboxymethyl cellulose filaments as defined in claim 1 and up to 50% by weight physiologically inert fibres.

12. A wound dressing according to any of claims 1 to 20 9 or 11, characterised in that the wound-contacting surface of the dressing is a fabric comprising carboxymethyl cellulose filaments.

13. A wound dressing according to claim 12, characterised in that the fabric is a nonwoven fabric.

25 14. A wound dressing according to claim 12 or claim 13, characterised in that the fabric has been prepared by reacting a fabric of cellulose filaments with a strong alkali and with monochloroacetic acid or a salt thereof.

15. A wound dressing according to claim 12, 30 characterised in that the fabric has been prepared by converting carboxymethyl cellulose filaments to fabric in a weaving, knitting or nonwoven fabric process.

- 20 -

16. Use in a wound dressing of absorbent fibres at the wound-contacting surface thereof, characterised in that the absorbent fibres are carboxymethyl cellulose filaments capable of absorbing at least 15 times their own weight of 5 0.9% by weight aqueous saline solution (as measured by the free-swell absorbency test) to form a transparent gel which retains sufficient fibrous character to be removed as a coherent dressing from a wound.

17. Use according to claim 16, characterised in that 10 the carboxymethyl cellulose filaments are at least 15 mm long.

18. Use in a wound dressing of absorbent carboxymethyl cellulose filaments at the wound-contacting surface thereof, substantially as herein described in any of 15 the foregoing Examples.

19. A process for the treatment of a traumatic, surgical or chronic wound which is exuding from its surface, characterised in that a wound dressing according to any of claims 1 to 15 is applied to the wound.

20 20. A process for the treatment of a traumatic, surgical or chronic wound which is exuding from its surface, characterised in that carboxymethyl cellulose filaments at least 15 mm long are applied to the wound, the filaments being capable of absorbing at least 15 times their own 25 weight of 0.9% by weight aqueous saline solution (as measured by the free-swell absorbency test) to form a transparent gel which retains sufficient fibrous character to be removed as a coherent dressing from the wound.

21. A process according to claim 20, characterised in 30 that a tow of carboxymethyl cellulose filaments or a rope of carboxymethyl cellulose filaments in staple fibre form is applied to the surface of the wound and spread out to cover the wound.

- 21 -

22. A process according to claim 20 for the treatment of a cavity wound, characterised in that a tow of carboxymethyl cellulose filaments or a rope of carboxymethyl cellulose filaments in staple fibre form is applied to fill 5 or line the inner surface of the cavity wound.

## INTERNATIONAL SEARCH REPORT

International Application No  
PC 94/00114A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 A61L25/00 A61L15/28 A61L15/60

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 405 324 (M. CRUZ) 20 September 1983 see claims; examples; tables ---	1-5,8-18
A	US,A,3 589 364 (W. DEAN) 9 October 1969 cited in the application see column 1, line 9 - line 44 see column 3, line 46 - column 4, line 9 ---	1-22
A	US,A,3 731 686 (P. CHATTERJEE) 8 May 1973 cited in the application see column 1, line 4 - line 17 see column 1, line 54 - line 68 ---	1-18
A	EP,A,0 344 913 (MINNESOTA MINING AND MANUFACTURING COMPANY) 6 December 1989 ---	
A	EP,A,0 199 531 (UNITIKA LTD.) 29 October 1986 ---	
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \* & \* document member of the same patent family

Date of the actual completion of the international search

26 April 1994

Date of mailing of the international search report

06.05.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Cousins-Van Steen, G



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 94/00114

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 092 999 (E.R. SQUIBB & SONS, INC.) 2 November 1983 cited in the application ---	
A	US,A,3 563 241 (F. EVANS) 16 February 1971 -----	

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 19-22 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 94/00114

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4405324	20-09-83	NONE	
US-A-3589364	29-06-71	BE-A- 729636	10-09-69
		CH-A- 381769	
		CH-B- 491140	31-05-70
		DE-A, B 1912740	09-10-69
		FR-A, B 2003895	14-11-69
		GB-A- 1236313	23-06-71
		JP-A- 54052189	24-04-79
		NL-A- 6903846	16-09-69
		SE-B- 385013	31-05-76
US-A-3731686	08-05-73	US-A- 3858585	07-01-75
EP-A-0344913	06-12-89	AU-A- 1966592	17-09-92
		AU-B- 630092	22-10-92
		AU-A- 3397989	07-12-89
		JP-A- 2026559	29-01-90
		US-A- 5197945	30-03-93
EP-A-0199531	29-10-86	JP-B- 5026498	16-04-93
		JP-A- 61240963	27-10-86
		US-A- 4651725	24-03-87
EP-A-0092999	02-11-83	AU-B- 569031	21-01-88
		AU-A- 1356583	27-10-83
		CA-A- 1220422	14-04-87
		DE-A- 3382538	07-05-92
		DE-A- 3382643	24-12-92
		EP-A- 0302536	08-02-89
		JP-B- 6013045	23-02-94
		JP-A- 58190446	07-11-83
		US-A- 4538603	03-09-85
		US-A- 4728642	01-03-88
US-A-3563241	16-02-71	NONE	

**THIS PAGE BLANK (USPTO)**